The EU Commission starts a market test on the proposed commitments offered by a pharmaceutical company to address the Commission’s concerns over excessive pricing on a range of off-patent cancer medicines (Aspen)

KEYWORDS
References

EU Commission, Aspen, Press Release, 14 July 2020

EU Commission, Aspen, Proposal for commitments to the EU Commission, Case AT.40394, 9 July 2020

Today, the European Commission (the Commission) started a market test inviting comments from interested parties on commitments offered by Aspen Pharmacare Holdings (Aspen) to address the Commission's concerns over excessive pricing for a range of off-patent cancer medicines (see, attached Commission press release). Broadly, Aspen’s proposed commitments are the following: a) Applying a price

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
    Belgium 141 contributions 48962 visits
  • Van Bael & Bellis (Brussels)
    Belgium 45 contributions 22851 visits
  • Van Bael & Bellis (Brussels)
    Belgium 44 contributions 21949 visits

Quotation

Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission starts a market test on the proposed commitments offered by a pharmaceutical company to address the Commission’s concerns over excessive pricing on a range of off-patent cancer medicines (Aspen), 14 July 2020, e-Competitions Remedies for unilateral conduct, Art. N° 95821

Visites 302

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues